Published on February 26, 2026, this international study represents a major collaboration between The Life Raft Group and thirty-five leading cancer centers across the U.S., Europe, and Japan to better understand treatment for gastrointestinal stromal tumors (GIST) with KIT exon 9 mutations.
Survey highlights show that most GIST patients receive mutational testing, but awareness of ctDNA testing remains low despite strong interest.
Understand why genetic testing is crucial for identifying and managing SDH-deficient GISTs, a rare and often hereditary tumor that requires specialized care.
The LRG and the Pediatric & SDH-Deficient GIST Consortium published a paper this February on Genomic Testing in SDH-deficient GIST.
ESMO 2024 Summary
Starting in January, every Wednesday will be dedicated learning about clinical trial process and to highlighting the groundbreaking clinical trials focused on gastrointestinal stromal tumors (GIST).
The LRG publishes, "Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry" Cancer Investigation ,Vol. 41, 2023. Issue 5 [...]
These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.
The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.
The Life Raft Group is committed to ensuring your GIST journey is as manageable as possible. We want to ensure that we expand our resources in order to help patients stay on their treatment longer by helping them to manage their side effects.
